Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply clinical-grade MagSense® nanoparticle formulations for the Company’s planned HER2 breast cancer human clinical studies.
View the ASX announcement, “Imagion Biosystems Secures Nanoparticle Manufacturer.”
Join Us at RSNA and SABCS: Advancing Molecular MRI for Cancer Detection
November 13, 2025
We are excited to announce that Imagion Biosystems (ASX: IBX) will be attending two premier medical conferences this fall: the Radiological Society of North